CDK4 and breast cancer: Several studies have reported that the presence of visceral metastases is associated with shorter survival compared with nonvisceral metastases in patients with breast cancer.46,47,48,49 Our study supports the negative association of visceral involvement with both PFS and OS in patients progressing during ET plus CDK4/6i treatment.